Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group

Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extraosseous tumors composed of malignant plasma cells without evidence of systemic Multiple Myeloma (MM). Radiotherapy (RT) +/- surgical excision (SE) is the treatment of choice, while additional sys...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144, p.4673-4673
Main Authors: Katodritou, Eirini, Kastritis, Efstathios, Dalampira, Dimitra, Kanellias, Nikolaos, Labropoulou, Vasiliki, Kyriakidis, Gerasimos, Douka, Vasiliki, Delimpasi, Sosana, Stoumpos, Dionysios, Spanoudakis, Emmanouil, Papageorgiou, Sotirios G., Fotiou, Despina, Migkou, Magdalini, Gkioka, Annita Ioanna, Triantafyllou, Theodora, Ntanasis-Stathopoulos, Ioannis, Papadopoulou, Theodosia, Tsirou, Kyriaki, Sevastoudi, Aggeliki, Daiou, Aikaterini, Theodorakakou, Foteini, Giannakoulas, Nikolaos, Pappa, Vasiliki, Lalayanni, Chrysavgi, Pouli, Anastasia, Kyrtsonis, Marie-Christine, Kotsopoulou, Maria, Verrou, Evgenia, Gavriatopoulou, Maria, Terpos, Evangelos, Dimopoulos, Meletios-Athanasios
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extraosseous tumors composed of malignant plasma cells without evidence of systemic Multiple Myeloma (MM). Radiotherapy (RT) +/- surgical excision (SE) is the treatment of choice, while additional systemic therapy (ST) has not been proven beneficial. Proposed risk factors for survival and progression to MM vary across studies, many of which have relatively short follow up and include patients diagnosed primarily before 2014. Our study aimed to examine outcomes and prognostic factors for survival and progression to MM in a large cohort of SP patients diagnosed over 30 years, and to assess the impact of various therapies applied in different timepoints. We analyzed 172 consecutive patients (pts), 115 with Solitary Bone Plasmacytoma (SBP) and 57 with Solitary Extramedullary Plasmacytoma (SEP). Male: female ratio was 84:88; median age was 62 years (17-85); 66% of cases were classified as SP and 34% as SP with minimal bone marrow involvement (i.e.
ISSN:0006-4971
DOI:10.1182/blood-2024-203776